Basilea Pharmaceutica 2017 Investor Presentation

Basilea Pharmaceutica is a fully integrated biopharmaceutical company focused on hospital medicines addressing drug resistance and non-response. The company markets two approved anti-infective products—isavuconazole (Cresemba) for invasive fungal infections and ceftobiprole (Zevtera/Mabelio) for bacterial infections—and is advancing two oncology programs in clinical development.